Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Huadong Medicine Partners with Excientia, a UK-based AI Drug Discovery Company

publication date: Sep 10, 2020

Huadong Medicine formed a partnership with Exscientia, an AI drug discovery company in the UK, to discover novel small-molecule candidates for oncology. The initial project is focused on transcription control of DNA damage response genes. The approach will treat patients with defective DNA damage repair mechanisms, a condition that leads to high mutation frequency, in patients with ovarian and breast cancer. The partnership will advance Huadong's strategic goal of developing innovative medicines. More details....

Stock Symbol: (SHZ: 0963)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China